4.3 Article

Modeling Alzheimer's Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR-SOB Scores From ADNI

Journal

Publisher

WILEY
DOI: 10.1038/psp.2013.54

Keywords

-

Funding

  1. ADNI (National Institutes of Health) [U01 AG024904]
  2. National Institute on Aging (NIA)
  3. National Institute of Biomedical Imaging and Bioengineering (NIBIB)
  4. Alzheimer's Association
  5. Alzheimer's Drug Discovery Foundation
  6. Bio-Clinica
  7. Biogen Idec
  8. Bristol-Myers Squibb Company
  9. Eisai
  10. Elan Pharmaceuticals
  11. Eli Lilly and Company
  12. F Hoffmann-La Roche
  13. Genentech
  14. GE Healthcare
  15. Innogenetics NV
  16. IXICO
  17. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  18. Johnson & Johnson Pharmaceutical Research & Development LLC.
  19. Medpace
  20. Merck Co.
  21. Meso Scale Diagnostics, LLC.
  22. NeuroRx Research
  23. Novartis Pharmaceuticals Corporation
  24. Pfizer
  25. Piramal Imaging
  26. Servier
  27. Synarc
  28. Takeda Pharmaceutical Company
  29. Canadian Institutes of Health Research
  30. NIH [P30AG010129, K01 AG030514]

Ask authors/readers for more resources

Disease-onset time (DOT) and disease trajectory concepts were applied to derive an Alzheimer's disease (AD) progression population model using the clinical dementia rating scale-sum of boxes (CDR-SOB) from the AD neuroimaging initiative (ADNI) database. The model enabled the estimation of a DOT and a disease trajectory for each patient. The model also allowed distinguishing fast and slow-progressing subpopulations according to the functional assessment questionnaire, normalized hippocampal volume, and CDR-SOB score at study entry. On the basis of these prognostic factors, 81% of the mild cognitive impairment (MCI) subjects could correctly be assigned to slow or fast progressers, and 77% of MCI to AD conversions could be predicted whereas the model described correctly 84% of the conversions. Finally, synchronization of the biomarker-time profiles on estimated individual DOT virtually expanded the population observation period from 3 to 8 years. DOT-disease trajectory model is a powerful approach that could be applied to many progressive diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available